Namenda neuropathic pain trial
Executive Summary
Forest will initiate a new Phase II trial of Namenda (memantine) for neuropathic pain, with a possible NDA submission by 2006. A previous Phase III study failed to show overall statistical significance in primary endpoint of nocturnal pain, although there was improvement in weekly assessments. Namenda was approved for treatment of moderate to severe Alzheimer's disease Oct. 16 (1"The Pink Sheet" Oct. 20, 2003, p. 3)...
You may also be interested in...
Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December
Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.